Clinical Computer Vision Biomarkers in Post-Acute Care

Can computer vision reveal what a patient can't say? Yes, **clinical computer vision biomarkers** offer a new way to understand patient health. These **clinical computer vision biomarkers**, analyzed by Digital Humans like GIA™, offer a new lens into patient health, particularly in post-acute and long-term care settings where subtle changes often signal significant underlying conditions. These biomarkers, derived from facial expressions, body language, and other visual cues, provide clinicians with objective data points that can supplement traditional assessments and improve the speed and accuracy of screening for 46 conditions. Learn how GIA™ and digitalhumanOS™ are transforming care.

What specific conditions can clinical computer vision biomarkers help detect?

Visual biomarkers are valuable for detecting underdiagnosed conditions in post-acute care, including mental health disorders. **Clinical computer vision biomarkers** can be particularly valuable in detecting conditions that are often underdiagnosed or misdiagnosed in post-acute care. These include mental health disorders like depression, anxiety, and PTSD. GIA™ screens for 46 conditions (24 live, 22 in clinical validation). The subtle changes in facial expressions and body language associated with these conditions can be difficult for clinicians to detect in a brief encounter, but GIA™'s computer vision capabilities can pick up on these nuances. For example, GIA™ screens for depression with AUC 0.816, PTSD at 80.0%, and anxiety at 77.5%. By identifying these conditions early, clinicians can develop targeted care plans and prevent further decline. Furthermore, visual biomarkers can aid in the assessment of neurological conditions, such as Parkinson's disease, where motor impairments and facial masking can be indicative of disease progression. Early detection of depression, anxiety, and PTSD can lead to targeted care plans. You can learn more about screening for depression, anxiety, and Parkinson's disease.

How does GIA integrate into existing clinical workflows?

GIA™ integrates into existing clinical operations, streamlining workflows rather than replacing them. GIA™ is designed to integrate into existing clinical operations, not replace them. GIA™ is bundled on Samsung Health Grade Galaxy devices with Samsung Knox. The screening process takes 40 seconds per patient, with results available in under 2 minutes. This efficiency allows facilities to screen more patients more frequently without overburdening staff. GIA™ speaks 92 languages, promoting patient comfort and engagement during the screening process. The results are then presented to clinicians for review and approval. GIA™ also integrates with major EHR systems like PointClickCare, Epic, Cerner, MatrixCare, Netsmart, and American HealthTech, ensuring that the data is readily accessible and can be incorporated into the patient's medical record. This integration helps to streamline clinical operations and improve communication among care team members. The 12.3M longitudinal PAC/LTC patient records inform GIA's analysis and improve screening over time. DigitalhumanOS™ ensures seamless integration.

What are the limitations of clinical computer vision biomarkers?

Clinical computer vision has limitations and should supplement, not replace, clinical judgment. While **clinical computer vision** offers significant benefits, it is important to acknowledge its limitations. GIA™ screens. She does not diagnose, treat, or prescribe. Her screenings are not a substitute for comprehensive clinical assessments. A clinician must always review and approve the results. Factors such as lighting conditions, video quality, and patient cooperation can affect the accuracy of the analysis. Additionally, the technology is constantly evolving, and further research is needed to validate its effectiveness across diverse patient populations and conditions. However, by understanding these limitations and using clinical computer vision as a supplement to traditional methods, clinicians can unlock new insights into patient health and improve the quality of care.

Conclusion

Clinical computer vision biomarkers represent a significant advancement in post-acute care, enhancing screening accuracy and potentially improving patient outcomes. By providing objective data points and enhancing screening accuracy, this technology can help clinicians detect hidden conditions and improve patient outcomes. GIA™ offers a practical and user-friendly way to incorporate these capabilities into your clinical operations. Are you ready to see what GIA™ can reveal about your patients' health? Learn more about the 46 conditions GIA™ screens for.